CTLA4 and lung carcinoma: Currently, the most studied immune checkpoints in lung cancer mainly include cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death receptor 1 (PD-1), and programmed cell death receptor ligand 1 (PD-L1), etc (Gubin et al., 2014; Steven et al., 2016).